Crosswalk Therapeutics, Inc.

United States of America

Back to Profile
1-11 of 11 for Crosswalk Therapeutics, Inc. Sort by
Query
Aggregations
Jurisdiction
        United States 10
        World 1
Date
New (last 4 weeks) 1
2025 February (MTD) 1
2025 January 1
2025 (YTD) 2
2024 1
See more
IPC Class
C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase 8
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases 6
A61K 9/00 - Medicinal preparations characterised by special physical form 5
A61K 38/00 - Medicinal preparations containing peptides 3
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells 3
See more
Status
Pending 5
Registered / In Force 6
Found results for  patents

1.

HUMAN ALPHA-GALACTOSIDASE VARIANTS

      
Application Number 18656340
Status Pending
Filing Date 2024-05-06
First Publication Date 2025-02-06
Owner Crosswalk Therapeutics, Inc. (USA)
Inventor
  • Agard, Nicholas J.
  • Miller, Mathew G.
  • Zhang, Xiyun
  • Huisman, Gjalt W.

Abstract

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

IPC Classes  ?

  • A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase

2.

ENGINEERED ACID ALPHA-GLUCOSIDASE VARIANTS

      
Application Number US2024036223
Publication Number 2025/007035
Status In Force
Filing Date 2024-06-28
Publication Date 2025-01-02
Owner CROSSWALK THERAPEUTICS, INC. (USA)
Inventor
  • Botham, Rachel, Cathleen
  • Cheung, Gordon, Michael
  • Hallows, William, Casey
  • Huisman, Gjalt, W.
  • Kruse, Nikki, D.
  • Lao, Jessica, P.
  • Maroju, Shilpa
  • Silverman, Adam, P.

Abstract

The present disclosure provides engineered acid alpha-glucosidase polypeptides, recombinant polynucleotides encoding the engineered acid alpha-glucosidase polypeptides, and method of using the engineered acid alpha-glucosidase polypeptides and the recombinant polynucleotides for therapeutic purposes.

3.

ENGINEERED ACID ALPHA-GLUCOSIDASE VARIANTS

      
Application Number 18611354
Status Pending
Filing Date 2024-03-20
First Publication Date 2024-07-11
Owner CROSSWALK THERAPEUTICS, INC. (USA)
Inventor
  • Hallows, William Casey
  • Botham, Rachel Cathleen
  • Zhu, Yu
  • Chng, Chinping
  • Dellas, Nikki
  • Huisman, Gjalt W.
  • Alaoui Ismaili, Moulay Hicham
  • Homan, David William
  • Silverman, Adam P.
  • Vroom, Jonathan
  • Lao, Jessica P.

Abstract

The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.

IPC Classes  ?

4.

HUMAN ALPHA-GALACTOSIDASE VARIANTS

      
Application Number 17814371
Status Pending
Filing Date 2022-07-22
First Publication Date 2022-11-10
Owner CROSSWALK THERAPEUTICS, INC. (USA)
Inventor
  • Hallows, William Casey
  • Vallieu, Kristen Jean
  • Dellas, Nikki
  • Zhu, Yu
  • Viduya, Judy Victoria Antonio
  • Chng, Chinping
  • Sero, Antoinette
  • Huisman, Gjalt W.
  • Botham, Rachel Cathleen
  • Alaoui Ismaili, Moulay Hicham

Abstract

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

IPC Classes  ?

  • C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

5.

HUMAN ALPHA-GALACTOSIDASE VARIANTS

      
Application Number 17186462
Status Pending
Filing Date 2021-02-26
First Publication Date 2021-09-02
Owner CROSSWALK THERAPEUTICS, INC. (USA)
Inventor
  • Hallows, William Casey
  • Dellas, Nikki
  • Zhu, Yu
  • Viduya, Judy Victoria Antonio
  • Chng, Chinping
  • Sero, Antoinette
  • Botham, Rachel Cathleen
  • Homan, David William
  • Alaoui Ismaili, Moulay Hicham
  • Vroom, Jonathan
  • Silverman, Adam P.
  • Vallieu, Kristen Jean
  • Reddy, Charu Shukla
  • Mccluskie, Kerryn

Abstract

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

IPC Classes  ?

  • C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C07K 1/14 - ExtractionSeparationPurification

6.

HUMAN ALPHA-GALACTOSIDASE VARIANTS

      
Application Number 17196858
Status Pending
Filing Date 2021-03-09
First Publication Date 2021-08-12
Owner CROSSWALK THERAPEUTICS, INC. (USA)
Inventor
  • Agard, Nicholas J.
  • Miller, Mathew G.
  • Zhang, Xiyun
  • Huisman, Gjalt W.

Abstract

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

IPC Classes  ?

  • A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
  • C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
  • A61K 9/00 - Medicinal preparations characterised by special physical form

7.

Engineered acid alpha-glucosidase variants

      
Application Number 17126647
Grant Number 11970722
Status In Force
Filing Date 2020-12-18
First Publication Date 2021-06-24
Grant Date 2024-04-30
Owner CROSSWALK THERAPEUTICS, INC. (USA)
Inventor
  • Hallows, William Casey
  • Botham, Rachel Cathleen
  • Zhu, Yu
  • Chng, Chinping
  • Dellas, Nikki
  • Huisman, Gjalt W.
  • Alaoui Ismaili, Moulay Hicham
  • Homan, David William
  • Silverman, Adam P.
  • Vroom, Jonathan
  • Lao, Jessica P.

Abstract

The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.

IPC Classes  ?

8.

Human alpha-galactosidase variants

      
Application Number 16985788
Grant Number 11497798
Status In Force
Filing Date 2020-08-05
First Publication Date 2020-12-31
Grant Date 2022-11-15
Owner CROSSWALK THERAPEUTICS, INC. (USA)
Inventor
  • Agard, Nicholas J.
  • Miller, Mathew G.
  • Zhang, Xiyun
  • Huisman, Gjalt W.

Abstract

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
  • A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

9.

Human alpha-galactosidase variants

      
Application Number 16985742
Grant Number 10973888
Status In Force
Filing Date 2020-08-05
First Publication Date 2020-11-19
Grant Date 2021-04-13
Owner CROSSWALK THERAPEUTICS, INC. (USA)
Inventor
  • Agard, Nicholas J.
  • Miller, Mathew G.
  • Zhang, Xiyun
  • Huisman, Gjalt W.

Abstract

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

IPC Classes  ?

  • C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
  • C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
  • A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
  • C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
  • A61K 9/00 - Medicinal preparations characterised by special physical form

10.

Human alpha-galactosidase variants

      
Application Number 16985761
Grant Number 11278600
Status In Force
Filing Date 2020-08-05
First Publication Date 2020-11-19
Grant Date 2022-03-22
Owner CROSSWALK THERAPEUTICS, INC. (USA)
Inventor
  • Agard, Nicholas J.
  • Miller, Mathew G.
  • Zhang, Xiyun
  • Huisman, Gjalt W.

Abstract

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

IPC Classes  ?

  • C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

11.

Human alpha-galactosidase variants

      
Application Number 16721102
Grant Number 11427813
Status In Force
Filing Date 2019-12-19
First Publication Date 2020-06-25
Grant Date 2022-08-30
Owner CROSSWALK THERAPEUTICS, INC. (USA)
Inventor
  • Hallows, William Casey
  • Vallieu, Kristen Jean
  • Dellas, Nikki
  • Zhu, Yu
  • Viduya, Judy Victoria Antonio
  • Chng, Chinping
  • Sero, Antoinette
  • Huisman, Gjalt W.
  • Botham, Rachel Cathleen
  • Alaoui Ismaili, Moulay Hicham

Abstract

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

IPC Classes  ?

  • C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
  • A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • A61K 38/00 - Medicinal preparations containing peptides